Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 1/2012

01.02.2012 | Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

Mendelian Randomization: Application to Cardiovascular Disease

verfasst von: Nicholas J. Timpson, Kaitlin H. Wade, George Davey Smith

Erschienen in: Current Hypertension Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

In the absence of an ethical, practical, and economical randomized trial, the epidemiologist is left to explore other methods in efforts to assert causality. An approach based on genotypic variation has the potential to mitigate against some of the problems found within conventional observational studies. Genetic variations associated with risk factors of interest at the population level can be used as proxy measures for these risk factors and to generate estimates of causal effect. The potential and the possible limitations of this approach within the cardiovascular field are presented in this review.
Literatur
1.
Raven PH, Johnson GB, Losos JB, Singer SR. Biology: seventh edition. McGraw-Hill Companies Publishers; 2005: chapter 44.
2.
• Brown IJ, Elliott P. Recent findings from Mendelian randomization studies of cardiovascular disease. Curr Cardio Risk Rep. 2010;4:429–36.CrossRef
3.
Davey Smith G, Ebrahim S. ‘Mendelian randomisation’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22.PubMedCrossRef
4.
Davey Smith G, Ebrahim S. Mendelian randomisation: prospects, potentials and limitations. Int J Epidemiol. 2004;33:30–42.CrossRef
5.
Davey Smith G, Timpson NJ, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med. 2008;40:524–41.CrossRef
6.
Davey Smith G, Lawlor DA, Harbord RM, Timpson NJ, Day I, et al. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. PLoS Med / Publ Libr Sci. 2007;4:e352.
7.
Lawlor DA, Harbord RM, Sterne JAC, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–63.PubMedCrossRef
8.
9.
Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29:722–9.PubMedCrossRef
10.
•• Timpson N, Harbord R, Davey Smith G, et al. Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using the FT0/MC4R genotype. Hypertension. 2009;54:84–90.PubMedCrossRef
11.
Brennan P, McKay J, Moore L, et al. Obesity and cancer: Mendelian randomization approach utilizing the FTO genotype. Int J Epidemiol. 2009;38:971–5.PubMedCrossRef
12.
Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposed to childhood and adult obesity. Science. 2007;316:889–94.PubMedCrossRef
13.
Scuteri A, Sanna S, Chen W, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genetics. 2007;20:e115.CrossRef
14.
Freathy RM, Timpson NJ, Lawlor DA, et al. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes. 2008;57:1419–26.PubMedCrossRef
15.
Loos RJF, Lindgren CM, Li S, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet. 2008;40:768–75.PubMedCrossRef
16.
Marmot MG, Elliott P, Shipley MJ, et al. Alcohol and blood pressure: the INTERSALT study. BMJ. 1994;308:1263–7.PubMedCrossRef
17.
Patel R, Lawlor DA, Whincup P, et al. The detection, treatment and control of high blood pressure in older British adults: cross-sectional findings from the British Women’s Heart and Health Study and the British Regional Heart Study. J Hum Hypertens. 2006;20:733–41.PubMedCrossRef
18.
Fuchs FD, Chambless LE, Whelton PK, et al. Alcohol consumption and the incidence of hypertension: the atheroschlerosis risk in Communities Study. Hypertension. 2001;37:1242–50.PubMed
19.
Moore RD, Levine DM, Southard J, et al. Alcohol consumption and blood pressure in the 1982 Maryland Hypertension Survey. Am J Hypertens. 1990;3:1–7.PubMed
20.
Chen L, Smith G, Harbord RM, et al. Alcohol intake and blood pressure; a systematic review implementing a Mendelian randomization approach. PLoS Med. 2008;5:e52.PubMedCrossRef
21.
Yoshida A, Huang IY, Ikawa M. Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci U S A. 1984;81:258–61.PubMedCrossRef
22.
Enomoto N, Takase S, Yasuhara M, Takada A. Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes. Alcohol Clin Exp Res. 1991;15:141–4.PubMedCrossRef
23.
Amamoto K, Okamura T, Tamaki S, et al. Epidemiologic study of the association of low-K-m mitochondrial acetaldehyde dehydrogenase genotypes with blood pressure level and the prevalence of hypertension in a general population. Hypertens Res. 2002;25:857–64.PubMedCrossRef
24.
Takagi S, Baba S, Iwai N, et al. The aldehyde dehydrogenase-2 gene is a risk factor for hypertension in Japanese but does not alter the sensitivity to pressor effects of alcohol: the Suita Study. Hypertens Res. 2001;24:365–70.PubMedCrossRef
25.
Kato N, Takeuchi F, Tabara Y, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nature Genetics 2011;43:531–538.PubMedCrossRef
26.
• Elliot P, Chambers JC, Zhang W, et al.. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37–48.CrossRef
27.
• The Emerging Risk Factors Collaboration (ERFC): C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.CrossRef
28.
Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199–204.PubMedCrossRef
29.
• Keavney B. C reactive protein and the risk of cardiovascular disease. BMJ Editorials. 2011;342:393–4.
30.
Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet. 2005;366:1954–9.PubMedCrossRef
31.
Lowe GD, Rumley A, Wannamethee SG. Hemostatic abnormalities associated with obesity and the metabolic syndrome. J Thromb Haemost. 2005;3:1076–8.CrossRef
32.
Frolich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population based study. Diabetes Care. 2000;23:1835–9.CrossRef
33.
Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–97.PubMedCrossRef
34.
Szalai AJ, Wu J, Lange EM, et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med. 2005;83:440–7.PubMedCrossRef
35.
Davey Smith G, Lawlor DA, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005;25:1051–6.PubMedCrossRef
36.
•• C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.CrossRef
37.
Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217–21.PubMedCrossRef
38.
•• Nordestgaard BG, Tybjærg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol. 2011;22:113–22.PubMedCrossRef
39.
Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38.PubMedCrossRef
40.
Linsel-Nitschke P, Samani NJ, Schunkert H. Sorting out cholesterol and coronary artery disease. N Engl J Med. 2010;363:2462–3.PubMedCrossRef
41.
• Musunuru K, Strong A, Frank-Kamenetsky M, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714–9.PubMedCrossRef
42.
Cohen JC, Boerwinkle E, Mosely Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.PubMedCrossRef
43.
Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707–13.PubMedCrossRef
44.
Waterworth DM, Ricketts SL, Song K, et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol. 2010;30:2264–76.PubMedCrossRef
45.
Hegele RA. Genome-wide association studies of plasma lipids: have we reached the limit? Arterioscler Thromb Vasc Biol. 2010;30:2084–6.PubMedCrossRef
46.
Musunuru K, Kathiresan S. Genetics of coronary artery disease. Annu Rev Genom Hum Genet. 2010;11:91–108.CrossRef
47.
Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of early onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334–41.PubMedCrossRef
48.
Linsel-Nitschke P, Heeren J, Aherrahrou Z, et al. Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis. 2010;208:183–9.PubMedCrossRef
49.
Polisecki E, Peter I, Simon JS, et al. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J Liposome Res. 2010;51:1201–7.
50.
Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010;55:2833–42.PubMedCrossRef
51.
Newton-Cheh C, Smith JG. What can human genetics teach us about the causes of cardiovascular disease? J Am Coll Cardiol. 2010;55:2843–5.PubMedCrossRef
52.
Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–9.PubMedCrossRef
53.
Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117:176–84.PubMedCrossRef
54.
Langsted A, Freiberg JJ, Tybjæg-Hansen A, et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med. 2011;270:65–75.PubMedCrossRef
55.
Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9.PubMedCrossRef
56.
Pare G, Anand SS. Mendelian randomisation, triglycerides, and CHD. Lancet. 2010;375:1584–6.PubMedCrossRef
57.
Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favourable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702–5.PubMedCrossRef
58.
Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299:2524–32.PubMedCrossRef
59.
Johannsen TH, Kamstrup PR, Andersen RV, et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab. 2009;94:1264–73.PubMedCrossRef
60.
The International Consortium for Blood Pressure genome-wide association studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011. doi:10.​1038/​nature10405.
61.
Jürgens G, Graudal NA. Effects of low sodium diet versus high sodium diet on blood pressure, rennin, aldosterone, catecholamines, cholesterols, and triglyceride. Cochrane Database Syst Rev. 2004;(1):CD004022. doi:10.​1002/​14651858.​CD004022.​pub2
62.
63.
64.
Intersalt Cooperative Research Group. Intersalt. An international study of electrolyte excretion and blood pressure: results for 24 h urinary sodium and potassium excretion. BMJ. 1998;297:319–28.
65.
Fava C, Montagnana M, Rosberg L, et al. Subjects heterozygous for genetic loss of function of the thiazide-sensitive co-transporter have reduced blood pressure. Hum Mol Genet. 2008;17:413–8.PubMedCrossRef
66.
67.
Tesson F, Leenen FHH. Still building on candidate-gene strategy in hypertension? Hypertension. 2007;50:607–8.PubMedCrossRef
68.
Büsst CJ, Scurrah KJ, Ellis JA, Harrap SB. Selective genotyping reveals association between the epithelial sodium channel γ-subunit and systolic blood pressure. Hypertension. 2007;50:672–8.PubMedCrossRef
69.
Barlassina C, Dal Fiume C, Lanzani C, et al. Common genetic variants and haplotypes in renal CLCNKA gene are associated to salt-sensitive hypertension. Hum Mol Genet. 2007;16:1630–8.PubMedCrossRef
70.
Khaw KT, Bingham S, Welch A, et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet. 2001;357:657–63.PubMedCrossRef
71.
Lawlor DA, Davey Smith G, Bruckdorfer KR, Kundu D, Ebrahim S. Those confounded vitamins: what can we learn from the difference between observational versus randomised trial evidence. Lancet. 2004;363:1724–7.PubMedCrossRef
72.
Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr. 1999;69:1086–107.PubMed
73.
• Timpson NJ, Forouhi NG, Brion MJ, et al. Genetic variation at the SLC23A1 locus is associated with circulating concentrations of L-ascorbic acid (vitamin C): evidence from 5 independent studies with >15,000 participants. Am J Clin Nutr. 2010;92:375–82.PubMedCrossRef
74.
Alderman M, Aiyer KJV. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin. 2004;1:369–79.CrossRef
75.
Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;1:1503–7.CrossRef
76.
Deveci OS, Kabakci G, Okutucu S, et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010;64:900–7.CrossRef
77.
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992. JAMA. 2000;10:2404–10.CrossRef
78.
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62:170–80.
79.
Meisinger C, Koenig W, Baumert J, Doring A. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study. Arterioscler Thromb Vasc Biol. 2008;1:1186–92.CrossRef
80.
Nakamura T, Tsubono Y, Kameda-Takemura K, et al. Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case–control study. Jpn Circ J. 2001;65:11–7.PubMedCrossRef
81.
Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Care Res. 2009;61:885–92.CrossRef
82.
Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40:437–42.PubMedCrossRef
83.
Wallace C, Newhouse SJ, Braund P, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet. 2008;82:139–49.PubMedCrossRef
84.
Wright AF, Rudan I, Hastie ND, Campbell H. A ‘complexity’ of urate transporters. Kidney Int. 2010;78:446–52.PubMedCrossRef
85.
McKeigue PM, Campbell H, Wild S, et al. Bayesian methods for instrumental variable analysis with genetic instruments (Mendelian randomization): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. Int J Epidemiol. 2010;39:907–18.PubMedCrossRef
86.
Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–72.PubMedCrossRef
87.
88.
89.
90.
Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41:77–81.PubMedCrossRef
91.
Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. [Erratum appears in Nat Genet 2010;42(5):464]. Nat Genet. 2010;42:105–16.
92.
Saccone SF, Al H, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16:36–49.PubMedCrossRef
93.
Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25. Nat Genet. 2008;40:616–22.PubMedCrossRef
94.
Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452:633–7.PubMedCrossRef
95.
Lui P, Vikis HG, Wang D, et al. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Canc Inst. 2008;100:1326–30.CrossRef
96.
Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–42.PubMedCrossRef
97.
Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5:e1000421.PubMedCrossRef
98.
•• Kaur-Knudsen D, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. Nicotinic acetylcholine receptor polymorphism, smoking behaviour, and tobacco-related cancer and lung and cardiovascular diseases: a cohort study. J Clin Oncol. 2011;21:2875–82.CrossRef
99.
Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med. 2008;5:1205–10.CrossRef
100.
Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40:755–64.PubMedCrossRef
101.
102.
Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Meth Med Res. 2011 Jan 7 (Epub ahead of print).
103.
Davey Smith G. Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health. Genes and Nutrition 2011;6:27–43.PubMedCrossRef
104.
Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42:937–50.PubMedCrossRef
Metadaten
Titel
Mendelian Randomization: Application to Cardiovascular Disease
verfasst von
Nicholas J. Timpson
Kaitlin H. Wade
George Davey Smith
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Hypertension Reports / Ausgabe 1/2012
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-011-0242-7

Weitere Artikel der Ausgabe 1/2012

Current Hypertension Reports 1/2012 Zur Ausgabe

Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

An Emerging Role of Degrading Proteinases in Hypertension and the Metabolic Syndrome: Autodigestion and Receptor Cleavage

Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

Epinephrine and the Metabolic Syndrome

Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

Between Candidate Genes and Whole Genomes: Time for Alternative Approaches in Blood Pressure Genetics

Pathogenesis of Hypertension (DT O’Connor, Section Editor)

Noninvasive Studies of Central Aortic Pressure

Vascular Mechanisms (FT Ruschitzka, Section Editor)

M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy

Vascular Mechanisms (F Ruschitzka, Section Editor)

MicroRNAs in Hypertension: Mechanisms and Therapeutic Targets

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise